Shalini Rao
Assistant Research Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
S1. FOXA1 redistribution in ESR1 mutant cells causes distinct ER-FOXA1 interaction.S2. FOXA1 gained peaks annotated genes are significantly associated with novel target genes.S3. FOXA1 redistribution in ESR1 mutant cells confers potential RXR binding sites.S4. RXR agonist LG100268 can promote colonization and growth of ESR1 mutant cells.S5. Clonogenic survival assay and 2D growth assay to test RXR response in Park and Gertz MCF7 cell models.S6. FOXA1 knockdown drastically attenuated the base line growth of both ESR1 WT and mutant cells.S7. RXR antagonist HX531 can inhibit the response of ESR1 mutant cells to RXR agonist.S8. RXR antagonist HX531 can inhibit the basal and agonist promoted growth of IPM-PDXO-073 organoid.
Year:
2025
Estrogen receptor alpha (ER/ESR1) mutations occur in 30-40% of endocrine resistant ER-positive (ER+) breast cancer. Forkhead Box A1 (FOXA1) is a key pioneer factor mediating ER-chromatin interactions and endocrine response in ER+ breast cancer, but its role in ESR1 mutant breast cancer remains unclear. Our previous FOXA1 ChIP-seq identified a large portion of redistributed binding sites in T47D genome-edited Y537S and D538G ESR1 mutant cells. Here, we further integrated FOXA1 genomic binding profile with the isogenic ER cistrome, accessible genome and transcriptome data of T47D cell model. FOXA1 redistribution was significantly associated with transcriptomic alterations caused by ESR1 mutations. Furthermore, in ESR1 mutant cells, FOXA1 binding sites less frequently overlapped with ER, and differential gene expression was less associated with the canonical FOXA1-ER axis. Motif analysis revealed a unique enrichment of retinoid X receptor (RXR) motifs in FOXA1 binding sites of ESR1 mutant cells. Consistently, ESR1 mutant cells were more sensitive to growth stimulation with the RXR agonist LG268. The mutant-specific response was dependent on two RXR isoforms, RXR-α and RXR-β, with a stronger dependency on the latter. In addition, T3, the agonist of thyroid receptor also showed a similar growth-promoting effect in ESR1 mutant cells. Importantly, RXR antagonist HX531 blocked growth of ESR1 mutant cells and a patient derived xenograft (PDX)-derived organoid with an ESR1 D538G mutation. Collectively, our data support evidence for a stronger RXR response associated with FOXA1 reprogramming in ESR1 mutant cells, suggesting development of therapeutic strategies targeting RXR pathways in breast tumors with ESR1 mutation. Implications: It provides comprehensive characterization of the role of FOXA1 in ESR1 mutant breast cancer and potential therapeutic strategy through blocking RXR activation.
Year:
2024
S1. FOXA1 redistribution in ESR1 mutant cells causes distinct ER-FOXA1 interaction. S2. FOXA1 gained peaks annotated genes are significantly associated with novel target genes. S3. FOXA1 redistribution in ESR1 mutant cells confers potential RXR binding sites. S4. RXR agonist LG100268 can promote colonization and growth of ESR1 mutant cells. S5. Clonogenic survival assay and 2D growth assay to test RXR response in Park and Gertz MCF7 cell models. S6. FOXA1 knockdown drastically attenuated the base line growth of both ESR1 WT and mutant cells. S7. RXR antagonist HX531 can inhibit the response of ESR1 mutant cells to RXR agonist. S8. RXR antagonist HX531 can inhibit the basal and agonist promoted growth of IPM-PDXO-073 organoid.
Year:
2024
S1. FOXA1 redistribution in ESR1 mutant cells causes distinct ER-FOXA1 interaction. S2. FOXA1 gained peaks annotated genes are significantly associated with novel target genes. S3. FOXA1 redistribution in ESR1 mutant cells confers potential RXR binding sites. S4. RXR agonist LG100268 can promote colonization and growth of ESR1 mutant cells. S5. Clonogenic survival assay and 2D growth assay to test RXR response in Park and Gertz MCF7 cell models. S6. FOXA1 knockdown drastically attenuated the base line growth of both ESR1 WT and mutant cells. S7. RXR antagonist HX531 can inhibit the response of ESR1 mutant cells to RXR agonist. S8. RXR antagonist HX531 can inhibit the basal and agonist promoted growth of IPM-PDXO-073 organoid.
Year:
2024
Year:
2023
Collaborators (8)
Jagmohan Hooda
Senior Research Project Director
University of Pittsburgh
Jason Carroll
Professor of Molecular Oncology
University of Cambridge
Jennifer Xavier
University of Pittsburgh
Adrian V. Lee
University of Pittsburgh
Steffi Oesterreich
UPMC Hillman Cancer Center
Jason Gertz
Professor
University of Utah School of Medicine
Daniel D Brown
Senior Research Scientist
University of Pittsburgh
Soleilmane Omarjee
Université Claude Bernard Lyon 1 - Domaine de Rockefeller
Make your next move.
Prepare your application
Review drafts before you send them.